Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05773703 · ClinicalTrials.gov registry record · Early Phase 1
Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer
A Early Phase 1 study, sponsored by Ratio Therapeutics.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 23
- Enrollment target
NCT05773703 is a Early Phase 1 study that has completed, run by Ratio Therapeutics. The registered enrollment target is 23 participants.
The verdict
NCT05773703, a Early Phase 1 study, has completed, sponsored by Ratio Therapeutics.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
Exploratory study in adult males with metastatic prostate cancer intended to characterize the pharmacokinetics and biodistribution of PSMA-Targeted \[In-111\]-Labeled Trillium Compounds with and without the cytoprotective agent PTI-122. Up to 36 eligible subjects will be enrolled. Additional subjects may be enrolled if there is insufficient data for evaluation, for example if the original study subjects do not complete required imaging studies for reasons unrelated to adverse events. Up to four PSMA-Targeted \[In-111\]-Labeled Trillium Compounds will be evaluated. Each compound will be evaluated first without the cytoprotective agent, PTI-122, then the \[In-111\]-labeled Trillium Compound may be co-administered with PTI-122.
Interventions
- DRUG PSMA-Targeted [In-111]-Labeled Trillium Compound
- DRUG PTI-122
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2022-12-08 |
| Est. Completion | 2023-12-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05773703
The ClinicalTrials.gov registry entry for NCT05773703 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ratio Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PSMA-Targeted [In-111]-Labeled Trillium Compound is the first listed.
NCT05773703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05773703 about?
NCT05773703 is a clinical study titled "Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer". Exploratory study in adult males with metastatic prostate cancer intended to characterize the pharmacokinetics and biodistribution of PSMA-Targeted \[In-111\]-Labeled Trillium Compounds with and without the cytoprotective agent PTI-122. Up to 36 eligible subjects will be enrolled. Additional subject...
What is the current status of trial NCT05773703?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 23 participants. The study started on 2022-12-08. Estimated completion is 2023-12-12.
What interventions are being tested in trial NCT05773703?
The interventions under investigation include: PSMA-Targeted [In-111]-Labeled Trillium Compound (DRUG), PTI-122 (DRUG).
Who is sponsoring clinical trial NCT05773703?
This trial is sponsored by Ratio Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.